GlassScriptPhysician profile
Andrew D Cash
NPI 1790782555
$8,012.90
in general payments reported to CMS, 2019-2025
50 companies · $854 in 2025
The $854 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $894 · 2021: $1,530 · 2022: $1,413 · 2023: $1,168 · 2024: $916 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.65 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Janssen Pharmaceuticals, INC | $896.97 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $677.02 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $621.90 | 2019-2025 | |
| Lilly USA, LLC | $593.36 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $534.07 | 2019-2025 | Airsupra |
| Astellas Pharma US INC | $503.37 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $492.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.83 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $293.29 | 2019-2023 | Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $259.77 | 2019-2022 | |
| Amgen INC. | $188.04 | 2019-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $119.78 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $110.51 | 2021-2023 | Proclaim, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $95.01 | 2022-2024 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.